Status:
COMPLETED
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)
Lead Sponsor:
AstraZeneca
Conditions:
Dyslipidaemia
Eligibility:
All Genders
Brief Summary
This is a multi-center survey of patients who are currently receiving lipid-lowering medications and have a moderate or higher cardiovascular (CV) risk. The survey will be conducted in the Russian Fed...
Detailed Description
This is a multi-center survey of patients who are currently receiving lipid-lowering medications and have a moderate or higher CV risk. The survey will be conducted in the Russian Federation. Data co...
Eligibility Criteria
Inclusion
- Properly obtained written informed consent from the potential subject.
- On lipid-lowering drug therapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days).
- Scheduled blood tests for total cholesterol (TC), HDL-C, LDL-C, glucose, creatinine, HbA1c, Hb, and hematocrit on the visit when they are considered for survey participation, or these tests must be decided to be necessary for study-unrelated purposes during that visit.
Exclusion
- Subjects who are unwilling or unable to provide written informed consent.
- The cognitive status of a potential subject and/or their home environment (in the investigator's opinion) might compromise the compliance with the treatment regimen during the past 8 weeks.
- A low CV risk.
- Participating in any other clinical trial.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
2700 Patients enrolled
Trial Details
Trial ID
NCT02230241
Start Date
September 1 2014
End Date
November 1 2015
Last Update
May 5 2016
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Belgorod, Russia
2
Research Site
Berdsk, Russia
3
Research Site
Domodedovo, Russia
4
Research Site
Engel's, Russia